Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Expenses: 2020-2025

Historic Operating Expenses for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $61.3 million.

  • 4D Molecular Therapeutics' Operating Expenses rose 19.83% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.5 million, marking a year-over-year increase of 36.88%. This contributed to the annual value of $187.9 million for FY2024, which is 40.64% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Operating Expenses stood at $61.3 million, which was up 3.03% from $59.5 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Operating Expenses' 5-year high stood at $61.3 million during Q3 2025, with a 5-year trough of $18.3 million in Q1 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Operating Expenses value was $42.5 million (recorded in 2024), while the average stood at $45.1 million.
  • Data for 4D Molecular Therapeutics' Operating Expenses shows a peak YoY skyrocketed of 57.69% (in 2021) over the last 5 years.
  • 4D Molecular Therapeutics' Operating Expenses (Quarterly) stood at $24.9 million in 2021, then increased by 20.56% to $30.0 million in 2022, then increased by 22.24% to $36.6 million in 2023, then soared by 53.19% to $56.1 million in 2024, then rose by 19.83% to $61.3 million in 2025.
  • Its Operating Expenses was $61.3 million in Q3 2025, compared to $59.5 million in Q2 2025 and $53.6 million in Q1 2025.